Schepens Eye Research Institute - Click to return to home page

Reza Dana, M.D., M.P.H., M.Sc.

Current Publications

Click here for a PubMed list of abstracts formatted by BioMed Central

From 4 books and monographs, 149 published papers, 57 chapters and reviews, and 30 abstracts

  1. Dana MR, Olkowski ST, Ahmadian H, Stark WJ, Young EM. Low-dose ultraviolet-B irradiation of donor corneal endothelium and graft survival. Invest Ophthalmol Vis Sci 1990; 31: 2261-2268.

  2. Dana MR, Moyes AL, Gomes JAP, Rosheim KM, Schaumberg DA, Sugar A, Holland EJ, Laibson PR, Sugar J. The indications for and outcome in pediatric keratoplasty: a multicenter study. Ophthalmology 1995; 102:1129-1138.

  3. Dana MR, Schaumberg DA, Kowal VA, Goren MB, Rapuano CJ, Cohen EJ, Laibson PR. Predictors of corneal neovascularization after penetrating keratoplasty. Cornea 1995; 14: 604-609.

  4. Dana MR, Yamada J, Streilein JW. Topical interleukin-1 receptor antagonist promotes corneal transplant survival. Transplantation 1997; 63:1501-1507.

  5. Dana MR, Schaumberg DA, Moyes AL, for the Multicenter Pediatric Keratoplasty Study Group. Keratoplasty for Peters anomaly and other mesenchymal dysgeneses. A multicenter study. Ophthalmology 1997;104: 1580-1586.

  6. Dana MR, Dai R, Zhu S, Yamada J, Streilein JW. Interleukin-1 receptor antagonist suppresses corneal Langerhans cell activity and promotes ocular immune privilege. Invest Ophthalmol Vis Sci 1998; 39:70-7.

  7. Dana MR, Zhu S, Yamada J. Topical modulation of interleukin-1 activity in corneal inflammatory neovascularization. Cornea 1998; 17: 403-409.

  8. Sullivan DA, Krenzer KL, Sullivan BD, Bazzinotti D, Toda I, Wickham LA, Dana MR. Does androgen insufficiency cause lacrimal gland inflammation and aqueous tear deficiency? Invest Ophthalmol Vis Sci. 1999; 40: 1261-1265.

  9. Dekaris I, Zhu S, Dana MR. Tumor nercrosis factor-alpha regulates corneal Langerhans cell migration. J Immunol 1999; 162: 4235-4239.

  10. Yamada J, Streilein JW, Dana MR. Role of tumor necrosis factor-alpha receptors TNFR-I (p55) and TNFR-II (p75) in corneal transplantation. Transplantation 1999; 68: 944-949.

  11. Zhu S, Dana MR. Expression of cell adhesion molecules on limbal and neovascular endothelium in corneal inflammatory neovascularization. Invest Ophthalmol Vis Sci. 1999; 40: 1427-1434.

  12. Zhu SN, Dekaris I, Duncker G, Dana MR. Early expression of proinflammatory cytokines after corneal transplantation. J Interferon Cytokine Res 1999; 19: 661-669.

  13. Yamagami S, Miyazaki D, Ono SJ, Dana MR. Differential chemokine gene expression in corneal transplant rejection. Invest Ophthalmol Vis Sci. 1999; 40: 2892-2897.

  14. Keane-Myers AM,  Miyazaki D, Liu G,  Dekaris I,  Ono SJ,  Dana MR.  Treatment with IL-1Ra prevents allergic eye disease. Invest Ophthalmol Vis Sci. 1999; 40: 3041-3046.

  15. Zhu SN, Yamada J, Streilein JW, Dana MR. ICAM-1 deficiency suppresses host allosensitization and rejection of MHC-disparate corneal transplants. Transplantation 2000; 69: 1008-10013.

  16. Dana MR, Qian Y, Hamrah P. Emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection. Cornea 2000; 19: 625-643.

  17. Yamada J, Streilein JW, Dana MR. Interleukin-1 Receptor Antagonist therapy and induction of Anterior Chamber Associated Immune Deviation-type tolerance after corneal transplantation. Invest Ophthalmol Vis Sci. 2000; 41: 4203-4208.

  18. Qian Y, Dekaris I, Yamagami S, Dana MR. Topical soluble tumor necrosis factor alpha receptor type I suppresses ocular chemokine gene expression and rejection of allogeneic corneal transplants. Arch Ophthalmol 2000; 118:1666-1671.

  19. Balaram M, Schaumberg D, Dana MR. Efficacy and tolerability outcomes after silicone punctal occlusion in dry eye syndromes. Am J Ophthalmol 2001; 131:30-36.

  20. Qian Y, Boisgerault F, Benichou G, Dana MR. Blockade of CD40-CD40L costimulatory pathway promotes survival of allogeneic corneal transplants. Invest Ophthalmol Vis Sci 2001; 42:987-994.

  21. Yamagami S, Dana MR. The critical role of draining lymph nodes in corneal alloimmunization and graft rejection. Invest Ophthalmol Vis Sci. 2001; 42: 1293-1298.

  22. Argueso P, Balaram M, Spurr-Michaud S, Keutmann HT, Dana MR, Gipson IK. Decreased levels of goblet cell mucin MUC5AC in tears of Sjogren’s syndrome patients. Invest Ophthalmol Vis Sci. 2002; 43: 1004-1011.

  23. Sakai R, Kawamoto S, Kinouchi T, Dana MR, Hamamoto T, Tsuru T, Yamagami S. Construction of Human Corneal Endothelial cDNA Library and Identification of Novel Active Genes. Invest Ophthalmol Vis Sci. 2002; 43: 1749-1756.

  24. Schaumberg DA, Sullivan DA, Dana MR. Hormone replacement therapy and the prevalence of dry eye syndrome in women. JAMA 2001; 286:2114-2119.

  25. Hamrah P, Zhang Q, Liu Y, Dana MR. Novel characterization of MHC class II-negative population of resident corneal Langerhans cells. Invest Ophthalmol Vis Sci. 2002; 43: 639-646.

  26. Yamagami S, Dana MR, Tsuru T. Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation. Cornea 2002; 21:405-409.

  27. Liu Y, Hamrah P, Zhang Q, Taylor AW, Dana MR. Draining lymph nodes of corneal transplant hosts exhibit evidence for donor MHC class II-positive dendritic cells derived from MHC class II-negative grafts. J Exp Medicine 2002; 195:259-268

  28. Qian Y, Dana MR. Effect of locally administered anti-CD154 (CD40L) monoclonal antibody on survival of allogeneic corneal transplants. Cornea 2002; 21:592-597.

  29. Qian Y, Hamrah P, Boisgerault F, Yamagami S, Vora S, Benichou B, Dana MR. Mechanisms of Immunotherapeutic Intervention by Anti-CD154 (CD40L) Antibody in High-Risk Corneal Transplantation. J Interfer Cytokine Res 2002: 2002; 22:1217-1225.

  30. Hamrah P, Liu Y, Dana MR. The corneal stroma is endowed with significant numbers of resident dendritic cells. Invest Ophthalmol Vis Sci. 2003: 44:581-9.

  31. Hamrah P, Huq S, Liu Y, Zhang Q, Dana MR. Corneal immunity is mediated by heterogeneous population of antigen-presenting cells. J Leuk Bio 2003; 4:172-176.

  32. Mendes F, Schaumberg DA, Navon S, Steinert R, Sugar J, Holland EJ, Dana MR. Assessment of Visual Function after Corneal Transplantation – The Quality of Life and Psychometric Assessment after Corneal Transplantation (Q-PACT) Study. Am J Ophthalmol 2003: 135:785-793.

  33. Hamrah P, Chen L, Zhang Q, Dana MR. Novel expression of vascular endothelial growth factor receptor (VEGFR)-3 and VEGF-c on corneal dendritic cells. Am J Path 2003: 163:57-68.

  34. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003: 136:318-326.

  35. Hamrah P, Liu Y, Qiang Z, Dana MR. Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation. Arch Ophthalmol. 2003; 121:1132-1140.

  36. Qian Y, Leong F, Kazlauskas A, Dana R. Ex Vivo Adenovirus-Mediated Gene Transfer to Corneal Graft Endothelial Cells in Mice. Investigative Ophthalmology and Vis Sci. 2004; 45:2187-2193.

  37. Barabino S, Dana MR. Animal models of dry eye: a critical assessment of opportunities and limitations. Invest Ophthalmol Vis Sci 2004: 45:1641-1646.

  38. Cursiefen C, Chen L, Borges L, Jackson D, Cao J, Radziejewski C, D’Amore P, Dana MR, Weigand SJ, Streilein JW. VEGF-A stimulates lymph- and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004;113:1040-1050.

  39. Dana MR. Corneal antigen-presenting cells: Diversity, plasticity, and disguise. The Cogan Lecture. Invest Ophthalmol Vis Sci 2004; 45:722-727.

  40. Cursiefen C, Chen L, Jackson D, Dana MR, Streilein JW. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Investigative Ophthalmology and Vis Sci 2004: 45:2666-2673.

  41. Barabino S, Chen W, Dana MR. Tear Film and Ocular Surface Tests in Animal Models of Dry Eye. Exp Eye Res 2004; 79:613-621.

  42. Lu Chen, Pedram Hamrah, Claus Cursiefen, Qiang Zhang, Bronislaw Pytowski, J. Wayne Streilein, Reza Dana. Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) Mediates Dendritic Cell Migration and Induction of Immunity to Corneal Transplants. Nature Med 2004: 10: 813-815.

  43. Hamrah P, Chen L, Zhang Q, Joyce NC, Dana MR. Novel identification of vascular endothelial growth factor receptor-3 (VEGFR-3) expression by monocytic bone marrow-derived cells in the conjunctiva. Exp Eye Res 2004; 79:553-561.

  44. Huq S, Liu Y, Benichou G, Dana MR. Relevance of the direct pathway of sensitization in corneal transplantation is dictated by the graft bed microenvironment. J Immunol 2004; 173:4464-4469.

  45. Yamagami S, Pedram Hamrah P, Dekaris I, Miyazaki D, Dawson T, Lu B, Gerard C, Dana MR. The CCR5 chemokine receptor mediates corneal Langerhans cell recruitment. Invest Ophthalmol Vis Sci. 2005; 46:1201-1207.

  46. Barabino S, Rashid S, Dana MR. The controlled environment chamber: A new mouse model for dry eyes. Invest Ophthalmol Vis Sci. 2005; 46:2766-2771.

  47. Chen L, Cursiefen C, Barabino S, Zhang Q, Dana MR. Novel Expression and Characterization of Lymphatic Vessel Endothelial Hyaluronate Receptor 1 (LYVE-1) by Conjunctival Cells. Invest Ophthalmol Vis Sci. 2005; 46:4536-4540.

  48. Beauregard C, Huq SO, Barabino S, Zhang Q, Kazlauskas A, Dana MR. Keratocyte apoptosis and failure of corneal allografts. Transplantation 2006; 81:1577-1582.

  49. Gulati A, Saccheti M, Bonini S, Dana R. Chemokine Receptor CCR5 Expression in Conjunctival Epithelium of Patients with Dry Eye Syndrome. Arch Ophthalmol 2006; 124: 710-716.

  50. Cursiefen C, Chen L, Saint-Geniez M, Hamrah P, Jin Y, Rashid S, Pytowski B, Persaud K, Wu Y, Streilein JW, Dana R. Nonvascular VEGFR-3 expression by corneal epithelium maintains avascularity and vision. Proc Nat Acad Sci USA 2006; 103:11405-11410.

  51. Schaumberg DA, Gulati G, Mathers WD, Clinch T, Lemp M, Nelson JD, Foulks GN, Dana R. Development and Validation of a Global Dry Eye Symptom Index. [Innovative Techniques and Technology] Ocular Surface 2007; 5:50-57.

  52. Chen L, Huq S, Gardner H, de Fougerolles AR, Barabino S, Dana MR. Very Late Antigen (VLA)-1 Blockade Markedly Promotes Survival of Corneal Allografts. Arch Ophthalmol 2007; 125:783-788.

  53. Hamrah P, ,†Yamagami S, Liu Y,  ‡Zhang Q, Vora SS, Lu B, Gerard CJ, Dana MR. Deletion of The chemokine receptor CCR1 prolongssuppresses corneal allorgrraft survival. Invest Ophthalmol Vis Sci. 2007; 48:1228-1236.

  54. Shen L, Barabino S, Taylor AW, Dana MR. The effect of the ocular microenvironment in regulating corneal dendritic cell maturation. Arch Ophthalmol 2007; 125: 908-915.

  55. Barabino S, Rolando M, Chen L, Dana MR. Exposure to a dry environment induces strain-specific responses in mice. Exp Eye Res 2007; 84:973-977.

  56. Collins JF, Dartt DA, Dana MR. Mist delivery of eye medication to the anterior segment. Am J Ophthalmol 2007; 144:137-139.

  57. Jin Y, Shen L, Chong EM, Hamrah P, Zhang Q, Chen L, Dana MR. The chemokine receptor CCR7 mediates corneal antigen-presenting cell trafficking. Mol Vision 2007;13: 626-634.

  58. Rashid S, Jin Y, Ecoiffier T, Barabino S, Schaumberg DA, Dana MR. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol 2008; 126: 219-225.

  59. Bachmann B, Bock F, Wiegand S, Maruyama K, Dana R, Kruse F, Luetjen-Drecoll E, Cursiefen C. VEGF-A neutralization after high-risk corneal transplantation promotes graft survival. Arch Ophthalmol 2008; 126: 71-77.

  60. Shen L, Jin Y, Freeman GJ, Sharpe AH, Dana MR. The function of donor versus recipient PD-L1 in corneal allograft survival. J Immunology 2007; 179: 3672-3679.

  61. Dana R. Comparison of topical interleukin-1 versus tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (AOS Thesis). Trans Am Ophthalmol Soc 2007; 105:330-343.

  62. Barcia R, Dana R, Kazlauskas A. Corneal graft rejection is accompanied by apoptosis of the endothelium and is prevented by gene therapy with Bcl-xL. Am J Transplantation, 2007; 7:2082-2089.

  63. Boisgérault F, Liu Y, Anosova N, Dana R, Benichou G. Differential roles of direct and indirect allorecognition pathways in the rejection of skin and corneal transplants. Transplantation 2008: in press.

  64. Ecoiffier T, El Annan J, Rashid S, Schaumberg DA, Dana R. Role of Alpha-4 Beta-1 Integrin (VLA-4) in Dry Eye Syndrome. Arch Ophthalmol  2008; 126:1695-9. PMID 19064851.

  65. Chauhan S, El Annan J, Ecoiffier T, Zhang Q, Saban DR, Dana R. Autoimmunity in Dry Eye is due to Resistance of Th17 to Treg Suppression. J Immunology; in press.

  66. Chung ES, Saban DR, Chauhan SK, Dana R. Regulation of blood versus lymphatic growth in the cornea. Invest Ophthalmol Vis Sci. 2008; PMID 19029028.

  67. Mantelli F, Schaffer L, Dana R, Argueso P. Glycogene expression in conjunctiva of patients with dry eye: downregulation of notch signaling. Invest Ophthalmol Vis Sci. 2008; PMID 19011014.

  68. Chauhan SK, Saban DR, Lee HK, Dana R. Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J Immunology; in press.

  69. Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of Dry Eye Disease among US Men: Estimates from the Physicians’ Health Studies. Arch Ophthalmol 2008; in press.

  70. Saban D, Chauhan S, Dana R. Chimeric keratoplasty promotes transplant survival. Am J Transplantation; in press.

  71. Chauhan S, El Annan J, Ecoiffier T, Zhang Q, Saban DR, Dana R. Autoimmunity in Dry Eye is due to Resistance of Th17 to Treg Suppression. J Immunology 2009; in press.

  72. Zhang X, Shen L, Jin Y, Saban DR, Chauhan SK, and Dana R. Depletion of passenger leukocytes from corneal grafts: An effective means of promoting transplant survival? Invest Ophthalmol Vis Sci, 2009; in press.

  73. Hamrah P, Haskova Z, Taylor AW, Zhang Q, Ksander BR, Dana MR. Local treatment with alpha-melanocyte stimulating hormone reduces corneal allorejection. Transplantation, in press.

 

SEO by Artio